MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
1.220
-0.010
-0.81%
After Hours: 1.238 +0.018 +1.46% 19:13 03/12 EDT
OPEN
1.230
PREV CLOSE
1.230
HIGH
1.270
LOW
1.200
VOLUME
137.23K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
1.020
MARKET CAP
12.31M
P/E (TTM)
-0.3334
1D
5D
1M
3M
1Y
5Y
1D
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
Benzinga · 21h ago
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
TipRanks · 2d ago
Soligenix SGX945 wins UK MHRA Promising Innovative Medicine designation for Behçet’s disease
Reuters · 2d ago
Soligenix says SGX945 granted PIM designation in UK by MHRA
TipRanks · 2d ago
Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease
Benzinga · 2d ago
SOLIGENIX ANNOUNCES SGX945 RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
Reuters · 2d ago
Weekly Report: what happened at SNGX last week (0302-0306)?
Weekly Report · 4d ago
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
TipRanks · 03/06 06:00
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.